In launching this blog earlier this year, we said that our goal would be to create a place to share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you and learn together. Now, as we approach our annual meeting, beginning Thursday, we think it's the perfect time and place to create opportunities for members of our community to be an active part of the conversation.
Most Recent Posts
Below, we sat down with Ellen Sigal, chairperson and founder of Friends of Cancer Research, for her thoughts about the upcoming PhRMA annual meeting.
1. What message are you bringing to the PhRMA annual meeting?
Later this week, PhRMA will be conducting our 2011 Annual Meeting, convening stakeholders from across the spectrums of healthcare, policy and regulation. Here, I speak with sanofi-aventis CEO Chris Viehbacher - who also serves as the chairman of PhRMA's board, about one of his priority issues for the meeting.
Can you tell us more about why prevention is one of the three themes of this year's PhRMA Annual Meeting?
04.11.11 | By Grady Forrer
Two Women Scientists Honored with PhRMA’s 2011 Discoverers Award
PhRMA's 2011 Annual Meeting starts this Wednesday in Jersey City, New Jersey. Few places in America have as many pharmaceutical research and biotechnology sector manufacturing and headquarters facilities or employ as many people as New Jersey.
This week marked the 20th anniversary of the New York Biotechnology Association annual meeting, featuring PhRMA President and CEO John Castellani as the keynote speaker.
I was struck by the significance of the number 20, as it indicates a good rough timeline of when biotechnology became a major influence in the life sciences sector.
Today is World Health Day. The theme of this year's activities is focused on the important health issue of bacteria that are resistant to current medicines. Today's events highlight the urgent need for new medicines to combat the growing number of bacteria that are resistant to antibiotics and the significant challenges that resistant bacteria pose to global public health.
Last night in DC, our president and CEO, John Castellani, and Sen. Jon Kyl were honored during the Bryce Harlow Foundation's 30th annual award dinner.
John Castellani was the recipient of the 2011 Bryce Harlow Business-Government Relations Award, which is given to individuals who have made "significant contributions to the advocacy profession through a lifelong career as an exemplary role model."
David Hyde Pierce - who played Niles Crane on Frasier - is in DC today to speak about the importance of government support for Alzheimer's disease research.
Huffington Post yesterday published an article listing the "10 Companies That Will Save the American Economy," choosing "those that are most likely to develop products and services which will allow global GDP [gross domestic product] growth to continue.
Just when you thought you knew enough about gene sequencing to at least smile knowingly if the phrase was dropped in conversation, now comes all the new stuff: Multiplexed deep sequencing, Fc-enhancement, emerging enabling OMIC technology platforms and new generation antibody conjugates.
The New York Times highlights Butler basketball coach (and apparently fairy godfather) Brad Stevens, who left a job in the biopharmaceutical research sector to try his hand at coaching. We love industry employees, but that might have been a pretty good move on his part. Plus, according to the article, "he still discusses developments in the pharmaceutical industry with former co-workers after church."
Rachel Hurley is the Executive Director of the Iowa Biotech Association and a partner of Innovate Iowa, a public-private partnership that includes senior leaders from biotech, academia, business, health and other organizations interested in growing Iowa's bioscience economy with a specific focus on advancing medical innovation.